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Introduction: Systemic lupus erythematosus is a multi-system connective tissue disorder. Peripheral neuropathy is a
known and underestimated complication in systemic lupus erythematosus. Ganglionopathy manifests when neuronal
cell bodies in the dorsal root ganglion are involved. Autoimmune disorders are a known etiology, with systemic lupus
erythematosus being a rare cause.
Case presentation: A 32-year-old South Asian woman presented with oral ulceration involving her lips following
initiation of treatment for a febrile illness associated with dysuria. She had a history of progressively worsening
numbness over a period of 4 months involving both the upper and lower limbs symmetrically while sparing the
trunk. Her vibration sense was impaired, and her reflexes were diminished. For the past 4 years, she had had a
bilateral, symmetrical, non-deforming arthritis involving the upper and lower limbs. Her anti-nuclear antibody and
anti-double-stranded deoxyribonucleic acid status were positive. Although her anti-Ro antibodies were positive,
she did not have clinical features suggestive of Sjögren syndrome. Nerve conduction studies revealed sensory
neuronopathy. A diagnosis of systemic lupus erythematosus complicated by sensory neuronopathy was made.
Treatment with intravenous immunoglobulin resulted in clinical and electrophysiological improvement.
Conclusion: Peripheral neuropathy in systemic lupus erythematosus can, by itself, be a disabling feature. Nerve
conduction studies should be considered when relevant. Neuropathy in systemic lupus erythematosus should be
given greater recognition, and rarer forms of presentation should be entertained in the differential diagnosis when
the clinical picture is atypical. Intravenous immunoglobulin may have role in treatment of sensory neuronopathy
in systemic lupus erythematosus.
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erythematosusIntroduction
Systemic lupus erythematosus (SLE) is a connective tissue
disorder that has the potential to cause disease in more
than one system. It may involve the autonomic, peripheral
or central nervous system. Though not given prominence
by clinicians, the peripheral nervous system involvement
could significantly affect patients’ quality of life [1]. Per-
ipheral neuropathy is known to occur in SLE at rates any-
where between 5% and 27% [2], but a sizeable number of
SLE patients (>50%) have subclinical nervous system in-
volvement detected only by nerve conduction studies
(NCSs) [3]. Conversely, affected small-diameter nerves will* Correspondence: rayno.navinan@gmail.com
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ings. Peripheral nervous system involvement is considered
a late feature [4] and is found with greater prevalence in pa-
tients with central nervous system involvement and in
those with high Systemic Lupus Erythematosus Disease Ac-
tivity Index scores. However, this perspective is at times
controversial and not agreed upon [1,3]. The exact patho-
physiology of peripheral neuropathy is unclear, and various
suggestions have been offered as to its origin, including me-
diation through anti-neuronal antibodies, anti-cardiolipin
antibodies and vasculitis with immune complex deposition
and subsequent damage [5,6]. In patients with SLE, periph-
eral neuropathy often occurs as a mild-natured, distal, sym-
metrical sensorimotor or sensory neuropathy, and less so
as severe and symptomatic mononeuritis multiplex andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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acute or chronic inflammatory demyelinating polyneurop-
athy [4,7,8]. Peripheral neuropathy in SLE patients is rarely
seen as a plexopathy [5] or sensory neuronopathy [9]. Sen-
sory neuronopathy causes a pure sensory disorder because
of the involvement of sensory neurons within the dorsal
root ganglion [10]. The degeneration is associated with
an inflammatory T-cell reaction driven mainly by a cell-
mediated immune response [11]. All sensory aspects maybe
affected, but proprioception and vibration are predomin-
antly impaired and the motor system is spared [12]. Other
signs include unsteady gait, pseudo-athetoid movements of
the hand [13], ataxia, areflexia and allodynia [12]. Although
relatively rare, sensory neuronopathy should be included in
the differential diagnosis of predominantly sensory or ataxic
neuropathies [12]. In our present report, we describe the
case of a patient with SLE who presented with peripheral
neuropathy secondary to sensory neuronopathy and dem-
onstrated an encouraging response to intravenous im-
munoglobulin (IVIG) treatment.
Case presentation
A 32-year-old South Asian woman presented to our hos-
pital with sudden-onset development of mouth ulcers in-
volving her oral cavity and lips following treatment for a
febrile episode associated with dysuria. She had a 4-year
prior history of recurrent symmetrical painful swelling of
small and large joints involving both upper and lower
limbs without deforming arthropathy. She had no symp-
toms or signs during that period. In the resource- and
investigation-limited peripheral hospital setting in Sri
Lanka, she was diagnosed as having seronegative rheuma-
toid arthritis and treated accordingly. Episodic relapses
were managed symptomatically with non-steroidal anti-
inflammatory agents and disease-modifying anti-rheumatic
drugs. During the 6 months preceding her presentation to
our hospital, she had a significant weight loss of 7kg and
developed numbness involving the lower and upper limbs
symmetrically over a period of 4 months, which caused sig-
nificant impairment of her activities of daily living. Her
symptoms progressively worsened, especially following the
current episode that led her to present to our hospital. Her
presenting complaint was attributed to hypothyroidism by
the previous investigating team, which found an elevated
thyroid-stimulating hormone level during her period of illness
(8.97μIU/ml (normal range, 0.497 μIU/ml to 4.5 μIU/ml)).
Following initiation of treatment of a suspected urinary tract
infection due to symptoms of fever and dysuria supported
by urinalysis findings, she developed mouth ulcers, which
were considered a drug reaction. While under investigation
and treatment, the patient developed an acute painful
swelling of the right calf which was confirmed to be deep
vein thrombosis (DVT). She had no history of xerostomia
or xerophthalmia at any given time during the diseasecourse. She had no high-risk behavior or habits such as al-
cohol consumption or smoking.
A general examination revealed that she was febrile and
had conjunctival edema and injection with oral mucosal
ulceration. Additionally, she had erythematous macules
and targetoid lesions over her face, palms and soles. The
lesions were progressive and involved her chest in the
form of erythematous dusky papules and patches. No
lymph nodes were observed. Her cardiovascular, respira-
tory and abdominal examinations were normal. A periph-
eral nervous system examination revealed diminished
vibration sense in both upper and lower limbs, and joint
proprioception was preserved. Two-point discrimination
distance was abnormal in both upper and lower limbs
(palms: 3cm on the right side and 2cm on the left side
(normal range, 0.8cm to 1.5cm); shins: 6cm bilaterally
(normal range, 3cm to 4cm)). Her stereognosis was im-
paired, but her graphesthesia remained intact. Although
her reflexes were diminished, her pain and soft touch
remained unaffected. Her muscle power and tone were
normal. The central nervous system findings were normal.
An investigation showed that the patient had an elevated
erythrocyte sedimentation rate (ESR) of 88mm for the first
hour. However, her C-reactive protein level was normal at
0.6mg/L (normal range, <5mg/L). Hematology examin-
ation revealed a bicytopenia, with a white blood cell count
of 1.74×109/L, a hemoglobin level of 8.8g/dl (normal
range, 11g/dl to 18g/dl) and a normal platelet count of
308×109/L. Repeated counts showed similar findings. A
bone marrow biopsy showed mild hypocellularity with ac-
tive hematopoiesis. Her serum iron level was normal at
87μg/dl (normal range, 37μg/dl to 148μg/dl). She had a
marginally low normal total iron binding capacity value of
274μg/dl (normal range, 274μg/dl to 386μg/dl) and nor-
mal iron saturation of 31.7% (normal range, 15% to 50%).
Her serum ferritin was elevated at 1,100μg/L (normal
range, 12μg/L to 190μg/L). Her alanine and aspartate ami-
notransaminase levels were elevated at 81IU/L (normal
range, 10IU/L to 35IU/L) and 79 IU/L (normal range,
10IU/L to 40IU/L), respectively, but her other liver param-
eters were within reference ranges. Her coagulation
screening results were normal, including activated partial
thromboplastin time. Repeat thyroid function tests were
within reference ranges. Her direct Coombs’ agglutination
test was negative. Her anti-nuclear antibody and anti-
double-stranded deoxyribonucleic acid (DNA) antibody were
both positive. Her anti-cardiolipin antibodies were positive
and moderately elevated at 57.9 (normal range, <15), but the
repeat value 12 weeks later was normal. Her complement
levels showed a marginally low normal complement compo-
nent 3 (C3) value of 55.4mg/dl (normal range, 55mg/dl to
120mg/dl) and a reduced C4 level of 11mg/dl (normal range,
20mg/dl to 50mg/dl). Her renal function was normal with a
serum creatinine of 0.71mg/dl (normal range, 0.50mg/dl to
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protein, and quantification demonstrated a urinary pro-
tein level of 139.1mg/dl, a urinary creatinine level of
68.4mg/dl and a urine protein/creatinine ratio of 2.08
(normal range, <0.4). An ultrasound of her abdomen
was normal and demonstrated normal-sized kidneys. A
renal biopsy revealed class III lupus nephritis. Retroviral
screening and venereal disease research laboratory
screening were negative. Anti Ro antibodies were found
to be positive. Hepatitis B surface antigen and hepatitis
C virus (HCV) antibodies were both negative. Epstein-
Barr virus (EBV) immunoglobulin M (IgM) antibodies
were positive. NCS revealed a sensory neuronopathy
(Figure 1). The two-dimensional echocardiogram, elec-
trocardiogram and chest X-ray were normal.
The patient was started on immunosuppressive treat-
ment with high-dose oral prednisolone (1mg/kg/day),
which was slowly tapered down; mycophenolate mofetilFigure 1 Patient summary report of preliminary nerve conduction stu
parameters suggestive of sensory neuronopathy. [NCV-nerve conductio
D- nerve conduction velocity normal distribution, SLE- systemic lupus eryth(250mg twice daily); and warfarin for anti-coagulation for
her DVT. She was examined 2 months later at a follow-up
appointment, but, owing to persistence of sensory neurono-
pathy without improvement, a clinical decision was made
to give a her trial of IVIG (0.4gm/kg/day) for 5 days. Upon
clinical reassessment 4 weeks later, she showed improve-
ment. NCSs were repeated, and the findings (Figure 2) par-
tially corroborated the observed clinical improvement.
Hematological parameters also showed clinical improve-
ment, with gradual reduction of her ESR. Her bicytopenia
had regressed, and repeat whole-blood analysis revealed
only mild persistent anemia with a normal white blood cell
count.
Discussion
In our present report, we describe the case of a patient with
a high Systemic Lupus Erythematosus Disease Activity
Index score of 26 (scores >12 define a severe flare) [14]dy taken at time of presentation shows electrophysiological
n velocity, EMG-electromyogram, NCS-nerve conduction study, NCV N.
ematosus, PN- peripheral neuropathy, R- right, L - left].
Figure 2 Post intravenous immunoglobulin nerve conduction study shows relative improvement in sensory electrophysiological
parameters in comparison to preliminary findings of sensory neuronopathy. [NCV-nerve conduction velocity, EMG-electromyogram,
NCS-nerve conduction study, NCV N.D- nerve conduction velocity normal distribution, IVIG- intravenous immunoglobulin, R- right, L - left].
Navinan et al. Journal of Medical Case Reports 2014, 8:141 Page 4 of 6
http://www.jmedicalcasereports.com/content/8/1/141complicated by DVT. The patient’s bicytopenia was
probably a complication of autoimmune bone marrow sup-
pression, as glucocorticoid treatment caused quick reversal
of the blood analysis. EBV could have been a subclinical in-
fection responsible for the patient’s IgM positivity, but it
could also have been an incidental finding. The disabling
(Additional file 1: Video 1) presentation of numbness
(Barthel Index activities of daily living score 45 of 100
[15]) prompted further investigation. The findings were
that of a sensory neuronopathy, which is a known compli-
cation of Sjögren syndrome (SS) but an uncommon mani-
festation of SLE.
Sensory neuronopathy is known to occur secondary to
neoplastic disorders, as a drug-induced phenomenon
(for example, as a reaction to cisplatin or vitamin B6)[16,17], in inherited disorders with degeneration of dorsal
root ganglion cells, following viral infections (for example,
human immunodeficiency virus (HIV), HCV, EBV) [18-20],
as an idiopathic phenomenon and in autoimmune diseases
(for example, SS, Miller Fisher syndrome and Bickerstaff ’s
brainstem encephalitis, chronic active hepatitis, and gluten
sensitivity) [13,21,22]. There is no reference standard for
diagnosing peripheral neuropathies. For sensory neurono-
pathy, various modalities have been suggested and tried.
Magnetic resonance imaging (MRI) can be useful, but is
non-specific and has technical issues that may cause vari-
ability results. Skin biopsy is also useful, as it may demon-
strate non-length-dependent involvement, especially in
difficult situations, but it is considered invasive and can be
done only in specialized centers. In patients with sensory
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pattern distinctively differentiates it from other sensory
neuropathies. Therefore, NCS findings can be very useful
in the differential diagnosis, though MRI and NCS find-
ings in combination can be considered virtually diagnostic
[11,12,23]. In patients with sensory neuronopathy, neuro-
physiological abnormalities are dominated by widespread
decrease in sensory nerve action potential amplitudes in-
volving both upper and lower limb nerves, even with an
asymmetrical or patchy distribution. This non-length-
dependent pattern of peripheral axonal degeneration with
impairment of sensory nerve conduction should be con-
sidered the hallmark of neuronopathies [23].
EBV can also result and present with a vast spectrum of
neurological manifestations, as it can involve the whole
neural axis, from central to peripheral, and affect any part
of the nervous system [24]. Positive serological findings
may be incidental because IgM antibodies are known to
remain positive for as long as 1 year. Though EBV cannot
be conclusively ruled out as a cause of neuronopathy, in
the absence of symptomatic infection, as reported by
Rubin et al. [20], SLE rather than EBV is likely to have
been the main cause underlying our patient’s presentation.
The pathophysiological mechanism of neuropathy var-
ies, depending on the type, as does the treatment recom-
mended to relieve patients’ symptoms [5]. Although
treatment with glucocorticoids, plasma exchange and
IVIG alone or in combination with mycophenolate mofetil
have been tried and suggested, the supporting evidence is
anecdotal at best because none of these regimens have
been studied in a controlled manner. There is also the
possibility of spontaneous stabilization and resolution
[14,25]. Chimeric monoclonal antibodies such as rituxi-
mab and infliximab have also been found to be useful
[26,27]. IVIG has been used successfully to treat many
neurological conditions effectively, either alone or in com-
bination with other agents [28]. It has also been shown to
be beneficial in the treatment of sensory neuronopathy,
even in patients with chronic conditions; however, SS was
the underlying disease in previously reported cases [29].
The use of IVIG to treat sensory neuronopathy due to
SLE is poorly described in the medical literature. As the
available evidence is based only on case reports and clear
protocols are lacking, questions arise as to the strength of
the evidence to support current treatment options. In our
patient, the level of her disability warranted intensive
treatment because her sensory neuronopathy did not show
spontaneous improvement or an acceptable response to
high-dose prednisolone and mycophenolate mofetil. A
trial of IVIG at 0.4gm/kg/day was given for a period 5 days.
When the patient was followed up 1 month later, she
demonstrated clinically definitive improvement (Barthel
Index activities of daily living score 70 of 100) and relative
improvement in two-point discrimination of the upperlimbs, 2cm on the right palm and 1.8cm on the left palm
(normal range, 0.8cm to 1.5cm). The electrophysiological
parameters of NCS supported these improvements. Our
patient’s response to treatment is in keeping with previous
successful attempts to treat neuronopathy [14,29]. Two
further cycles of IVIG are pending in our patient, though
cost is a limiting factor. Even though evidence is based
predominantly on case reports, the positive response to
IVIG merits recognition and further study, because, to the
best of our knowledge, this report describes the first case
with encouraging results in which IVIG was trialed in a
patient with sensory neuronopathy due to SLE.
When SLE patients complain of neuropathy, attempts
should be made to classify and identify the type of per-
ipheral neuropathy. Care should be taken not to over-
look the possibility of connective tissue disease as the
etiology of peripheral neuropathy, because it may easily
be attributed to other causes. Our patient’s clinical pic-
ture did not fully match a classical sensory neuronopa-
thy, even though her motor system remained unaffected.
This presentation demonstrates that, although the cli-
nical features may point toward a sensory neuronopathy,
investigations such as NCS are invaluable in helping to
confirm a diagnosis when the presentation is atypical.
Conclusions
Peripheral neuropathy in SLE, although poorly appreci-
ated, can be a disabling manifestation. SLE patients should
be screened routinely for neuropathy, even if they are
asymptomatic, and, when neuropathy is present, NCS may
help in identifying its type. Though uncommon, when
pure sensory symptoms and clinical signs dominate, sen-
sory neuronopathy should be considered in the differential
diagnosis. IVIGs may have a role in the treatment of
sensory neuronopathy, even in SLE patients.
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